MDGL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 1377 min ago

@ $230.59

Wydano: 3 geg. 2024 @ 22:13

Zwrot: -0.33%

Poprzedni sygnał: geg. 3 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 3.24 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	433 785
Średni wolumen	612 738
Kapitalizacja rynkowa	4.83B
EPS	$-5.68 ( 2024-02-29 )
Następna data zysków	( $-6.06 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.50
ATR14	$12.98 (5.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Taub Rebecca	Buy	2 676	Common Stock
2024-04-08	Taub Rebecca	Sell	224	Common Stock
2024-04-08	Taub Rebecca	Sell	945	Common Stock
2024-04-08	Taub Rebecca	Sell	300	Common Stock
2024-04-08	Taub Rebecca	Sell	600	Common Stock

INSIDER POWER
-31.13
Last 100 transactions
Buy: 220 053 \| Sell: 418 887

Wolumen Korelacja

Długi: -0.74 (moderate negative)

Krótki: 0.11 (neutral)

Signal:(48) Neutral

Madrigal Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
GOSS	0.82

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Madrigal Pharmaceuticals Korelacja - Waluta/Towar

0.04
( neutral )

-0.61
( weak negative )

-0.15
( neutral )

0.13
( neutral )

0.26
( neutral )

0.83
( strong )

Madrigal Pharmaceuticals Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-527 000 (0.00 %)
EPS:	$-19.99

FY	2023
Przychody:	$0
Zysk brutto:	$-527 000 (0.00 %)
EPS:	$-19.99

FY	2022
Przychody:	$0
Zysk brutto:	$-467 000 (0.00 %)
EPS:	$-17.47

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-14.63

Financial Reports:

No articles found.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Aktualne aktualizacje dla Madrigal Pharmaceuticals [MDGL]

Upcoming Earnings Alert